The antiserum was produced against synthesized peptide derived from human PLCG2 around the phosphorylation site of Tyr753. AA range:721-770

Phospho-PLC γ2 (Y753) Polyclonal Antibody detects endogenous levels of PLC γ2 protein only when phosphorylated at Y753.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):SLyDV

PLCG2

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2

PLCG2 ;
1-phosphatidylinositol 4 ;
5-bisphosphate phosphodiesterase gamma-2 ;
Phosphoinositide phospholipase C-gamma-2 ;
Phospholipase C-IV ;
PLC-IV ;
Phospholipase C-gamma-2 ;
PLC-gamma-2

The protein encoded by this gene is a transmembrane signaling enzyme that catalyzes the conversion of 1-phosphatidyl-1D-myo-inositol 4 ,5-bisphosphate to 1D-myo-inositol 1 ,4 ,5-trisphosphate (IP3) and diacylglycerol (DAG) using calcium as a cofactor. IP3 and DAG are second messenger molecules important for transmitting signals from growth factor receptors and immune system receptors across the cell membrane. Mutations in this gene have been found in autoinflammation , antibody deficiency , and immune dysregulation syndrome and familial cold autoinflammatory syndrome 3. [provided by RefSeq , Mar 2014] ,

Catalytic activity:1-phosphatidyl-1D-myo-inositol 4 ,5-bisphosphate + H (2) O = 1D-myo-inositol 1 ,4 ,5-trisphosphate + diacylglycerol. ,cofactor:Calcium. ,Function:The production of the second messenger molecules diacylglycerol (DAG) and inositol 1 ,4 ,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signaling. ,PTM:Phosphorylated on tyrosine residues; upon ligand-induced activation of a variety of growth factor receptors and immune system receptors. Increases phospholipase activity. ,similarity:Contains 1 C2 domain. ,similarity:Contains 1 PH domain. ,similarity:Contains 1 PI-PLC X-box domain. ,similarity:Contains 1 PI-PLC Y-box domain. ,similarity:Contains 1 SH3 domain. ,similarity:Contains 2 SH2 domains. ,

intracellular ,cytosol ,plasma membrane ,extracellular exosome ,

>>Inositol phosphate metabolism ;
>>Metabolic pathways ;
>>EGFR tyrosine kinase inhibitor resistance ;
>>ErbB signaling pathway ;
>>Ras signaling pathway ;
>>Calcium signaling pathway ;
>>Chemokine signaling pathway ;
>>NF-kappa B signaling pathway ;
>>HIF-1 signaling pathway ;
>>Phosphatidylinositol signaling system ;
>>Phospholipase D signaling pathway ;
>>Axon guidance ;
>>VEGF signaling pathway ;
>>Osteoclast differentiation ;
>>Platelet activation ;
>>Neutrophil extracellular trap formation ;
>>C-type lectin receptor signaling pathway ;
>>Natural killer cell mediated cytotoxicity ;
>>B cell receptor signaling pathway ;
>>Fc epsilon RI signaling pathway ;
>>Fc gamma R-mediated phagocytosis ;
>>Leukocyte transendothelial migration ;
>>Neurotrophin signaling pathway ;
>>Inflammatory mediator regulation of TRP channels ;
>>Thyroid hormone signaling pathway ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Growth hormone synthesis , secretion and action ;
>>Vibrio cholerae infection ;
>>Epithelial cell signaling in Helicobacter pylori infection ;
>>Shigellosis ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Glioma ;
>>Non-small cell lung cancer ;
>>Hepatocellular carcinoma